This week
Suggest a nameObligation Marketing for AI Builders
The 7-Rung LadderThe 8-Type TaxonomyWrapper or WinnerThe Sample ColumnThe Signal
Updated through the day. Every headline links straight to the source. The two lines underneath are ours.
This is the underrated pattern: use wet lab data to close the loop on model reliability. Leash caught that their models were confabulating chemistry by checking against real experiments. For biotech builders using agents, this is your playbook: pair inference with measurement. The data that teaches chemists also teaches AI to stop lying.
This is exactly the agent use case that matters: massively parallel analysis of high-dimensional data where human triage is the bottleneck. The partnership legitimacy (Scripps) adds weight. For researchers: this playbook is portable to your domain if you have similar data scale. For investors: biotech + AI agents is a real category now, not speculation. If you have data science infrastructure to rent, build for this.
This is a vertical play. OpenAI is not just selling API access anymore, it's building domain expertise and locked-in workflows in biotech. For builders in biopharma: this means OpenAI will have a native advantage in that vertical. For investors: this is how foundation model companies transition from utilities to applications. Expect similar moves from Anthropic and others.
This is the model-to-molecule workflow that biotech founders should be watching. If DeepMind can materially speed up antimicrobial discovery, the applications pipeline across pharma and biodefense just got shorter. The real test is whether candidates from this pipeline actually survive clinical testing.
This is how wet-lab AI should work: real experimental data becomes the ground truth that catches model hallucinations, then turns into training signal for chemistry agents. The DEL (display) assay is tedious and failure-prone, which makes it perfect leverage for AI—Leash is showing how. For builders in biotech: if you're training agents on chemistry, your training data needs to be grounded in assay results, not just structure prediction. This is the operational model.